Merck CEO indicates interest in GLP-1 combination therapies, may pursue deals
Not wanting to be left out in the cold, Merck now plans to pursue GLP-1 combination therapies amid growing excitement about the lucrative potential of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.